DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation
Status:
Active, not recruiting
Trial end date:
2024-05-06
Target enrollment:
Participant gender:
Summary
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor
efficacy, safety, tolerability and pharmacokinetics of DZD9008 in participants with locally
advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has
progressed on prior platinum-based chemotherapy